<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02416102</url>
  </required_header>
  <id_info>
    <org_study_id>20140722</org_study_id>
    <secondary_id>R01HL133240</secondary_id>
    <secondary_id>R01HL139365</secondary_id>
    <nct_id>NCT02416102</nct_id>
  </id_info>
  <brief_title>Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis</brief_title>
  <official_title>Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flight Attendant Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of Losartan on cigarette smoke-induced&#xD;
      lung injury in smokers and ex-smokers with and without chronic obstructive pulmonary disease&#xD;
      (COPD).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty in recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">March 31, 2016</start_date>
  <completion_date type="Actual">April 3, 2017</completion_date>
  <primary_completion_date type="Actual">April 3, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Nasal Potential Difference (NPD).</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>NPD were assessed from nasal cells collected using sterile cytology brushes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in IL-8 Concentrations</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Interleukin (IL)-8 concentrations were analyzed from samples on nasal lavage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in TGF-ß mRNA Expression</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Transforming Growth Factor (TGF)-ß messenger ribonucleic acid (mRNA) expression were analyzed from nasal cells samples.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>COPD</condition>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Healthy non-smokers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Smokers without COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ex-smokers with COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan 50 mg</intervention_name>
    <description>50 mg Losartan taken orally once daily for 4 consecutive weeks.</description>
    <arm_group_label>Ex-smokers with COPD</arm_group_label>
    <arm_group_label>Healthy non-smokers</arm_group_label>
    <arm_group_label>Smokers without COPD</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan 100 mg</intervention_name>
    <description>50 mg Losartan taken orally twice daily for 4 consecutive weeks.</description>
    <arm_group_label>Ex-smokers with COPD</arm_group_label>
    <arm_group_label>Healthy non-smokers</arm_group_label>
    <arm_group_label>Smokers without COPD</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fulfill one of the group definitions above&#xD;
&#xD;
          2. Age between 35 and 75 years old&#xD;
&#xD;
          3. Clinical diagnosis of chronic bronchitis, defined as productive cough for at least 3&#xD;
             months per year for at least two consecutive years&#xD;
&#xD;
          4. Stable maintenance of all current medication therapy for 3 months, including ARBs for&#xD;
             treated groups&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Current therapy with Angiotensin-converting-enzyme (ACE) inhibitor,or Intolerance to&#xD;
             Angiotensin II receptor blockers (ARB)&#xD;
&#xD;
          2. Women of child bearing potential&#xD;
&#xD;
          3. Current use of nonsteroidal antiinflammatory drugs or potassium supplementation,&#xD;
             treatment with aliskiren, anticoagulation&#xD;
&#xD;
          4. COPD exacerbation requiring treatment within 6 weeks of the screening visit&#xD;
&#xD;
          5. Oral corticosteroid use within 6 weeks of the screening visit&#xD;
&#xD;
          6. Significant hypoxemia (oxygen saturation &lt;90% on room air), chronic respiratory&#xD;
             failure by history (pCO2 &gt; 45 mmHg) and forced expiratory volume in 1 second (FEV1)&#xD;
             below 40%, clinical evidence of cor pulmonale&#xD;
&#xD;
          7. Untreated arterial hypertension (systolic blood pressure &gt;140 mm Hg, diastolic blood&#xD;
             pressure &gt; 90 mm Hg)&#xD;
&#xD;
          8. Ability to understand and willingness to sign consent documents&#xD;
&#xD;
          9. Blood pressure less than 100 mm Hg systolic or 70 mm Hg diastolic while standing at&#xD;
             the screening visit&#xD;
&#xD;
         10. Cardiac, renal, hepatic (LFTs &gt; 3x normal upper limit), neurological, psychiatric,&#xD;
             endocrine or neoplastic diseases that are at the discretion of the investigator, to&#xD;
             interfere with participation in study&#xD;
&#xD;
         11. History of renal artery stenosis&#xD;
&#xD;
         12. Concomitant airway disorders other than COPD and chronic bronchitis, such as&#xD;
             bronchiectasis and asthma (history and reversible airflow obstruction by American&#xD;
             Thoracic Society (ATS) criteria)&#xD;
&#xD;
         13. History of pulmonary malignancies, and any other malignancies in the last 5 years&#xD;
&#xD;
         14. History of thoracic surgery.&#xD;
&#xD;
         15. Acute pulmonary exacerbation within 6 weeks from the Screening Visit.&#xD;
&#xD;
         16. Subjects with no airflow obstruction by spirometry but with a decrease in diffusing&#xD;
             capacity of lung for carbon monoxide(DLco) possibly indicating emphysema.&#xD;
&#xD;
         17. Significant exposure to environmental tobacco smoke or atmospheric or occupational&#xD;
             pollutants&#xD;
&#xD;
         18. Urine pregnancy positive test at the Screening Visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafael Calderon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>April 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2015</study_first_posted>
  <results_first_submitted>August 7, 2020</results_first_submitted>
  <results_first_submitted_qc>August 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2020</results_first_posted>
  <disposition_first_submitted>June 26, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>August 1, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 12, 2019</disposition_first_posted>
  <last_update_submitted>August 7, 2020</last_update_submitted>
  <last_update_submitted_qc>August 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rafael Calderon Candelario</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02416102/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Non-smokers</title>
          <description>10 healthy non-smokers will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg once daily (QD) for 4 weeks&#xD;
losartan 100 mg: 50 mg twice daily (BID) for 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Smokers Without COPD</title>
          <description>10 smokers without Chronic Obstructive Pulmonary Disease (COPD) will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Ex-smokers With COPD</title>
          <description>10 ex-smokers with COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There was a difficulty in recruitment ex-smokers with COPD prior to study termination</population>
      <group_list>
        <group group_id="B1">
          <title>Healthy Non-smokers</title>
          <description>10 healthy non-smokers will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Smokers Without COPD</title>
          <description>10 smokers without COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Ex-smokers With COPD</title>
          <description>10 ex-smokers with COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Nasal Potential Difference (NPD).</title>
        <description>NPD were assessed from nasal cells collected using sterile cytology brushes.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Nasal sample data for all participants were not available as the readings were uninterpretable and not further analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Non-smokers</title>
            <description>10 healthy non-smokers will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Smokers Without COPD</title>
            <description>10 smokers without COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Ex-smokers With COPD</title>
            <description>10 ex-smokers with COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nasal Potential Difference (NPD).</title>
          <description>NPD were assessed from nasal cells collected using sterile cytology brushes.</description>
          <population>Nasal sample data for all participants were not available as the readings were uninterpretable and not further analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IL-8 Concentrations</title>
        <description>Interleukin (IL)-8 concentrations were analyzed from samples on nasal lavage</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>No participants were recruited in the Ex-Smokers with COPD due to difficulty in recruitment prior to study termination. Only 5 participants were analyzed for the Healthy Non-Smokers and Smokers without COPD arms as only 5 in each group had complete sets of samples that could be analyzed due to bad quality/quantity available.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Non-smokers</title>
            <description>10 healthy non-smokers will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Smokers Without COPD</title>
            <description>10 smokers without COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Ex-smokers With COPD</title>
            <description>10 ex-smokers with COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IL-8 Concentrations</title>
          <description>Interleukin (IL)-8 concentrations were analyzed from samples on nasal lavage</description>
          <population>No participants were recruited in the Ex-Smokers with COPD due to difficulty in recruitment prior to study termination. Only 5 participants were analyzed for the Healthy Non-Smokers and Smokers without COPD arms as only 5 in each group had complete sets of samples that could be analyzed due to bad quality/quantity available.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2867" spread="1685"/>
                    <measurement group_id="O2" value="4676" spread="1948"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in TGF-ß mRNA Expression</title>
        <description>Transforming Growth Factor (TGF)-ß messenger ribonucleic acid (mRNA) expression were analyzed from nasal cells samples.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>No participants were recruited in the Ex-Smokers with COPD due to difficulty in recruitment prior to study termination. Only 5 participants were analyzed for the Healthy Non-Smokers and Smokers without COPD arms as only 5 in each group had complete sets of samples that could be analyzed due to bad quality/quantity available.</population>
        <group_list>
          <group group_id="O1">
            <title>Healthy Non-smokers</title>
            <description>10 healthy non-smokers will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Smokers Without COPD</title>
            <description>10 smokers without COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Ex-smokers With COPD</title>
            <description>10 ex-smokers with COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in TGF-ß mRNA Expression</title>
          <description>Transforming Growth Factor (TGF)-ß messenger ribonucleic acid (mRNA) expression were analyzed from nasal cells samples.</description>
          <population>No participants were recruited in the Ex-Smokers with COPD due to difficulty in recruitment prior to study termination. Only 5 participants were analyzed for the Healthy Non-Smokers and Smokers without COPD arms as only 5 in each group had complete sets of samples that could be analyzed due to bad quality/quantity available.</population>
          <units>percentage change in mRNA expression</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51" spread="31"/>
                    <measurement group_id="O2" value="-23" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 Weeks</time_frame>
      <desc>Only treatment-emergent Adverse Events will be reported as per treating physician discretion.</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Non-smokers</title>
          <description>10 healthy non-smokers will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Smokers Without COPD</title>
          <description>10 smokers without COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Ex-smokers With COPD</title>
          <description>10 ex-smokers with COPD will receive 50 mg of losartan for 4 weeks followed by 100 mg of losartan for 4 weeks&#xD;
Losartan 50 mg: 50 mg QD for 4 weeks&#xD;
losartan 100 mg: 50 mg BID for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthias Salathe, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>913-588-6000</phone>
      <email>msalathe@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

